Three things to know:
1. The Ottawa, Canada-based company is in the pre-clinical stage of developing a biomaterial that uses plant-derived cellulose to generate “scaffold architectures” for regenerative medicine.
2. Spiderwort’s biomaterials demonstrated promise for the treatment of spinal cord injuries and soft tissue regeneration in pre-clinical trials.
3. The company, which recently moved into a biotechnology research facility in Ottawa, plans to use the funding to reach clinical trials.
More articles on biologics:
How Dr. Vladimir Sinkov opened his solo spine practice in the midst of the COVID-19 pandemic
Steadman Clinic moves to absorb hospital orthopedic group — 6 things to know
Michigan group to open 7th location, add 2 orthopedic surgeons
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
